Lan­theus hands Per­spec­tive Ther­a­peu­tics $28M up­front to ex­pand its ra­dio­phar­ma op­tions

Ra­dio­phar­ma com­pa­ny Lan­theus is look­ing to build up its port­fo­lio through a col­lab­o­ra­tion with Per­spec­tive Ther­a­peu­tics. By hand­ing Per­spec­tive $28 mil­lion up­front, Lan­theus has the ex­clu­sive op­tion to se­cure a li­cens­ing deal for an al­pha-tar­get­ed ther­a­py in neu­roen­docrine tu­mors.

As for Seat­tle-based Per­spec­tive, it is tak­ing over Lan­theus’ ra­dio­phar­ma man­u­fac­tur­ing fa­cil­i­ty in Som­er­set, NJ for an undis­closed price. In Au­gust last year, Lan­theus said it was wind­ing down this site, ac­cord­ing to an SEC fil­ing. Lan­theus is in the ra­dioac­tive di­ag­nos­tic and imag­ing space, with sev­er­al ther­a­peu­tic as­sets in its re­search pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER